Yueren Yan1,2,3,4, Zhendong Gao1,2,3,4, Han Han1,2,3,4, Yue Zhao1,2,3,4, Yang Zhang1,2,3,4, Xiangyi Ma1,2,3,4, Haiquan Chen5,6,7,8. 1. Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China. 2. Institute of Thoracic Oncology, Fudan University, Shanghai, 200032, China. 3. State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, 200433, China. 4. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. 5. Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China. hqchen1@yahoo.com. 6. Institute of Thoracic Oncology, Fudan University, Shanghai, 200032, China. hqchen1@yahoo.com. 7. State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, 200433, China. hqchen1@yahoo.com. 8. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. hqchen1@yahoo.com.
Abstract
PURPOSE: NRAS plays a pivotal role in progression of various kinds of somatic malignancies; however, the correlation between NRAS and lung adenocarcinoma is less known. We aim to analyze the prognostic value of NRAS expression in lung adenocarcinoma, and explore the relationship between NRAS and tumor immune microenvironment. METHODS: We obtained the transcriptome profiles and clinical data of LUAD from The Cancer Genome Atlas database and three Genome Expression Omnibus datasets. Specimens from 325 patients with completely resected lung adenocarcinoma were collected for immunohistochemical assays of NRAS, PD-L1, PD-1 and TIM-3. Then, we performed gene set enrichment analysis to investigate cancer-related and immune-related signaling pathways. TIMER algorithms were performed to evaluate tumor immune infiltrating cells and immune-related biomarkers. RESULTS: Compared with adjacent non-tumor tissue, NRAS expression was significantly upregulated in LUAD tissue. NRAS expression was significantly correlated with more advanced stage and positive lymph nodes. Kaplan-Meier curves and Cox analysis suggested that high NRAS expression led to a poor prognosis, and could be an independent prognostic factor in LUAD patients. Besides, NRAS expression was positively correlated with CD8+ T cells, macrophages, and neutrophils, and negatively correlated with B cells and CD4+ T cells. The expression level of NRAS was positively correlated with PD-L1, PD-1, and TIM-3 both at RNA and protein level. CONCLUSIONS: To conclude, we found NRAS is a novel prognostic biomarker in LUAD. Besides, the expression level of NRAS may influence the prognosis of LUAD via various kinds of cancer-related pathways and remodeling TIM.
PURPOSE: NRAS plays a pivotal role in progression of various kinds of somatic malignancies; however, the correlation between NRAS and lung adenocarcinoma is less known. We aim to analyze the prognostic value of NRAS expression in lung adenocarcinoma, and explore the relationship between NRAS and tumor immune microenvironment. METHODS: We obtained the transcriptome profiles and clinical data of LUAD from The Cancer Genome Atlas database and three Genome Expression Omnibus datasets. Specimens from 325 patients with completely resected lung adenocarcinoma were collected for immunohistochemical assays of NRAS, PD-L1, PD-1 and TIM-3. Then, we performed gene set enrichment analysis to investigate cancer-related and immune-related signaling pathways. TIMER algorithms were performed to evaluate tumor immune infiltrating cells and immune-related biomarkers. RESULTS: Compared with adjacent non-tumor tissue, NRAS expression was significantly upregulated in LUAD tissue. NRAS expression was significantly correlated with more advanced stage and positive lymph nodes. Kaplan-Meier curves and Cox analysis suggested that high NRAS expression led to a poor prognosis, and could be an independent prognostic factor in LUAD patients. Besides, NRAS expression was positively correlated with CD8+ T cells, macrophages, and neutrophils, and negatively correlated with B cells and CD4+ T cells. The expression level of NRAS was positively correlated with PD-L1, PD-1, and TIM-3 both at RNA and protein level. CONCLUSIONS: To conclude, we found NRAS is a novel prognostic biomarker in LUAD. Besides, the expression level of NRAS may influence the prognosis of LUAD via various kinds of cancer-related pathways and remodeling TIM.
Authors: Malgorzata Banys-Paluchowski; Karin Milde-Langosch; Tanja Fehm; Isabell Witzel; Leticia Oliveira-Ferrer; Barbara Schmalfeldt; Volkmar Müller Journal: Breast Cancer Res Treat Date: 2019-10-23 Impact factor: 4.872
Authors: Jeremy J W Chen; Pei-Li Yao; Ang Yuan; Tse-Ming Hong; Chia-Tung Shun; Min-Liang Kuo; Yung-Chie Lee; Pan-Chyr Yang Journal: Clin Cancer Res Date: 2003-02 Impact factor: 12.531
Authors: Khalid I Al-Shibli; Tom Donnem; Samer Al-Saad; Magnus Persson; Roy M Bremnes; Lill-Tove Busund Journal: Clin Cancer Res Date: 2008-08-15 Impact factor: 12.531
Authors: Elisabeth Brambilla; Gwénaël Le Teuff; Sophie Marguet; Sylvie Lantuejoul; Ariane Dunant; Stephen Graziano; Robert Pirker; Jean-Yves Douillard; Thierry Le Chevalier; Martin Filipits; Rafael Rosell; Robert Kratzke; Helmut Popper; Jean-Charles Soria; Frances A Shepherd; Lesley Seymour; Ming Sound Tsao Journal: J Clin Oncol Date: 2016-02-01 Impact factor: 44.544
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Amira A Barkal; Rachel E Brewer; Maxim Markovic; Mark Kowarsky; Sammy A Barkal; Balyn W Zaro; Venkatesh Krishnan; Jason Hatakeyama; Oliver Dorigo; Layla J Barkal; Irving L Weissman Journal: Nature Date: 2019-07-31 Impact factor: 49.962